Comparison Of Laboratory Examination Results And Clinical Manifestations In Post Chemotherapy Folfox Regimens And Capeox Regimens In Colorectal Cancer Patients At Ibnu Sina Educational Hospital Umi Wakaf Foundation Macassar
DOI:
https://doi.org/10.51601/ijhp.v5i1.363Abstract
Colorectal cancer (CRC) is the fourth leading cause of death in the world, often associated with an unhealthy diet, including low consumption of fruits, vegetables, and fiber, and high intake of red meat. This study aims to compare the results of laboratory examinations and clinical manifestations in patients undergoing chemotherapy using Folfox and CapeOX regimens at Ibnu Sina Teaching Hospital, UMI Waqf Foundation, Makassar. The method used was descriptive design with cross-sectional approach and purposive sampling technique. The results showed that in Folfox regimen chemotherapy patients, there were 90.9% with low erythrocytes and 95.5% with low hemoglobin, while in CapeOX regimen, 59.1% of patients had low erythrocytes. Of the 22 patients in each regimen, 14 patients (Folfox) and 9 patients (CapeOX) reported complaints. Comparison of leukocyte examination between the two regimens showed a significant association with a p-value of 0.044 (p<0.05), while examination of erythrocytes, platelets, hemoglobin, blood sugar, and clinical manifestations did not show a significant association (p>0.05). This study provides insight into the impact of each chemotherapy regimen on the patient's condition.
References
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., Grem, J. L., Haste, P., Hecht, J. R., Hoffe, S., Hunt, S., Hussan, H., Johung, K. L., Joseph, N., Kirilcuk, N., Jones, F. (2024). Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(2D). https://doi.org/10.6004/jnccn.2024.0029
Cassidy, J. (2007). Capecitabine Plus Oxaliplatin in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 25(31), 5043–5045. https://doi.org/10.1200/JCO.2007.13.4676
Cercek, A., Goodman, K. A., Hajj, C., Weisberger, E., Segal, N. H., Reidy-Lagunes, D. L., Stadler, Z. K., Wu, A. J., Weiser, M. R., Paty, P. B., Guillem, J. G., Nash, G. M., Temple, L. K., Garcia-Aguilar, J., & Saltz, L. B. (2014). Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer. Journal of the National Comprehensive Cancer Network, 12(4), 513–519. https://doi.org/10.6004/jnccn.2014.0056
Chen, Z.-X., Li, J., Liu, W.-B., Zhang, S.-R., & Sun, H. (2022). Elemene-Containing Hyperthermic Intraperitoneal Chemotherapy Combined with Chemotherapy for Elderly Patients with Peritoneal Metastatic Advanced Gastric Cancer. World Journal of Clinical Cases, 10(5), 1498–1507. https://doi.org/10.12998/wjcc.v10.i5.1498
Degirmencioglu, S., Tanrıverdi, O., Demiray, A. G., Senol, H., Dogu, G. G., & Yaren, A. (2019). Retrospective Comparison of Efficacy and Safety of CAPOX and FOLFOX Regimens As Adjuvant Treatment in Patients With Stage III Colon Cancer. Journal of International Medical Research, 47(6), 2507–2515. https://doi.org/10.1177/0300060519848258
Fei, Z., Lijuan, Y., Xi, Y., Wei, W., Jing, Z., Miao, D., & Shuwen, H. (2019). Gut Microbiome Associated with Chemotherapy-Induced Diarrhea From The Capeox Regimen as Adjuvant Chemotherapy in Resected Stage III Colorectal Cancer. Gut Pathogens, 11(1), 18. https://doi.org/10.1186/s13099-019-0299-4
Fu, G., Tang, Z., Xu, Z., & Zhang, S. (2023). Case Report: Primary Small Bowel Adenocarcinoma with Peritoneal Metastasis Responded Well to A Capeox + Bevacizumab Regimen. Frontiers in Gastroenterology, 2. https://doi.org/10.3389/fgstr.2023.1187194
Gill, S., Ko, Y.-J., Cripps, C., Beaudoin, A., Dhesy-Thind, S., Zulfiqar, M., Zalewski, P., Do, T., Cano, P., Lam, W. Y. H., Dowden, S., Grassin, H., Stewart, J., & Moore, M. (2016). PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. Journal of Clinical Oncology, 34(32), 3914–3920. https://doi.org/10.1200/JCO.2016.68.5776
Gilshtein, H., Ghuman, A., Dawoud, M., Yellinek, S., Kent, I., Sharp, S. P., Nagarajan, A., & Wexner, S. D. (2021). Total Neoadjuvant Treatment for Rectal Cancer: Preliminary Experience. The American Surgeon, 87(5), 708–713. https://doi.org/10.1177/0003134820951499
Hannan, L. M., Yoong, J., Chong, G., & Mcdonald, C. F. (2012). Interstitial Lung Disease in A Patient Treated With Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) For Metastatic Colorectal Cancer. Radiology and Oncology, 46(4). https://doi.org/10.2478/v10019-012-0006-2
Hong, Y. S., Kim, H. J., Park, S. J., Kim, K., Lee, J., Park, J. H., Kim, J. H., Lim, S., Yu, C. S., Kim, J. C., Baek, J. Y., Kim, S. Y., & Kim, T. W. (2013). Second‐Line Cetuximab/Irinotecan Versus Oxaliplatin/Fluoropyrimidines For Metastatic Colorectal Cancer With Wild‐Type KRAS. Cancer Science, 104(4), 473–480. https://doi.org/10.1111/cas.12098
Iveson, T. J., Kerr, R. S., Saunders, M. P., Cassidy, J., Hollander, N. H., Tabernero, J., Haydon, A., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Scudder, C., Boyd, K. A., Briggs, A., Waterston, A., Medley, L., Wilson, C., Ellis, R., Essapen, S., Paul, J. (2018). 3 Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Combination Therapy For Colorectal Cancer (SCOT): An International, Randomised, Phase 3, Non-Inferiority Trial. The Lancet Oncology, 19(4), 562–578. https://doi.org/10.1016/S1470-2045(18)30093-7
Joo, H. J., Lee, H. S., Jang, B. I., Kim, D. B., Kim, J. H., Park, J. J., Kim, H. G., Baek, I. H., Lee, J., & Kim, B. (2023). Sex‐Specific Differences in Colorectal Cancer: A Multicenter Retrospective Cohort Study. Cancer Reports, 6(8). https://doi.org/10.1002/cnr2.1845
Lai, Y.-H., Chang, Y.-T., Chang, Y.-J., Tsai, J.-T., Li, M.-H., & Lin, J.-C. (2023). Predictive Value of the Interaction between CEA and Hemoglobin in Neoadjuvant CCRT Outcomes in Rectal Cancer Patients. Journal of Clinical Medicine, 12(24), 7690. https://doi.org/10.3390/jcm12247690
Li, Z., Yin, D.-F., Wang, W., Zhang, X.-W., Zhou, L.-J., & Yang, J. (2021). Efficacy of Yiqi Jianpi Anti-Cancer Prescription Combined With Chemotherapy in Patients with Colorectal Cancer After Operation. World Journal of Clinical Cases, 9(32), 9869–9877. https://doi.org/10.12998/wjcc.v9.i32.9869
Liberty, I. A. (2024). Metode Penelitian Kesehatan. Penerbit NEM.
Lim, H. J., Gill, S., Speers, C., Melosky, B., Barnett, J., Fitzgerald, C., O’Reilly, S., & Kennecke, H. (2009). Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study. Journal of Oncology Practice, 5(4), 153–158. https://doi.org/10.1200/JOP.0942001
Maeda, O., Matsuoka, A., Furukawa, K., Miyahara, R., Hirooka, Y., & Ando, Y. (2019). Alterations in Gene Expression and DNA Methylation Profiles in Gastric Cancer Cells Obtained From Ascitic Fluids Collected Before and After Chemotherapy. Molecular and Clinical Oncology, 11(1), 91–98. https://doi.org/10.3892/mco.2019.1858
McLeod, S. (2019). Sampling Methods | Types and Techniques Explained. Simply Psychology.
Melani, R., Darmawan, E., & Raharjo, B. (2019). Gambaran Hubungan Regimen Dosis Danefek Samping Kemoterapi pada Pasien Kanker di RSUD Prof Dr. Margono Soekarjo Purwokerto Periode Bulan Januari-Februari Tahun 2019. Majalah Farmaseutik, 15(2), 113. https://doi.org/10.22146/farmaseutik.v15i2.47664
Notoatmodjo. (2012). Metode Penelitian Kesehatan. Rineka Cipta.
Osawa, H., Handa, N., & Minakata, K. (2015). Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 22(5), 325–331. https://doi.org/10.3727/096504015X14410238486522
Ryu, C.-G., Jung, E.-J., Kim, G., Kim, S. R., & Hwang, D.-Y. (2011). Oxaliplatin-Induced Pulmonary Fibrosis: Two Case Reports. Journal of the Korean Society of Coloproctology, 27(5), 266. https://doi.org/10.3393/jksc.2011.27.5.266
Sadahiro, S., Suzuki, T., Okada, K., Saito, G., Miyakita, H., Ogimi, T., Chan, L. F., & Kamei, Y. (2020). Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. Oncology, 98(9), 637–642. https://doi.org/10.1159/000507293
Sato, A., Sato, Y., Hiruta, N., Oshiro, T., Yoshida, Y., Urita, T., Kitahara, T., Kadoya, K., Nabekura, T., Moriyama, Y., & Okazumi, S. (2022). Signet-Ring Cell Carcinoma of The Appendix with Ganglioneuromatosis: A Case Report. Surgical Case Reports, 8(1), 151. https://doi.org/10.1186/s40792-022-01509-3
Shin, S. J., Lee, J., Chung, I.-J., Kim, T. W., Chun, H. G., Shin, D., Kim, Y. H., Song, H.-S., Han, S.-W., Kim, J. G., Kim, S. Y., Choi, Y. J., & Chung, H. C. (2013). A Phase II Open-Label Randomized Multicenter Trial of TSU-68 In Combination With S-1 and Oxaliplatin Versus S-1 in Combination with Oxaliplatin in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 31(4_suppl), 492–492. https://doi.org/10.1200/jco.2013.31.4_suppl.492
Swarjana, I. K. (2016). Metode Penelitian Kesehatan. Andi Offset.
Turner, D. P. (2020). Sampling Methods in Research Design. Headache: The Journal of Head and Face Pain, 60(1), 8–12. https://doi.org/10.1111/head.13707
Yamai, T., Ikezawa, K., Kawamoto, Y., Hirao, T., Higashi, S., Daiku, K., Maeda, S., Abe, Y., Urabe, M., Kai, Y., Takada, R., Nakabori, T., Uehara, H., & Ohkawa, K. (2022). 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu. Current Oncology, 29(4), 2644–2649. https://doi.org/10.3390/curroncol29040216
Yucel, K. B. (2023). Prognostic Significance of the Gustave-Roussy Immune Score in Colon Cancer Patients Treated with Adjuvant CAPEOX Regimen. Eurasian Journal of Medical Investigation, 7(4), 433–439. https://doi.org/10.14744/ejmi.2023.93298
Zhang, H., You, J., Liu, W., Chen, D., Zhang, S., & Wang, X. (2021). The Efficacy and Safety of Bevacizumab Combined With FOLFOX Regimen in The Treatment of Advanced Colorectal Cancer. Medicine, 100(30), e26714. https://doi.org/10.1097/MD.0000000000026714
Zhao, X., He, Z. R., Han, P. Y., Cai, Z. H., Fu, Z. W., Zhang, L. Y., Sun, J., Ma, J. J., Dong, F., Zang, L., & Zheng, M. H. (2022). Efficacy of Neoadjuvant Capeox/Mfolfox6 without Radiation For Patients with Baseline Resectable Mid–Low Locally Advanced Rectal Cancer. Journal of Digestive Diseases, 23(12), 695–704. https://doi.org/10.1111/1751-2980.13156
Zhou, M., Thompson, T. D., Lin, H.-Y., Chen, V. W., Karlitz, J. J., Fontham, E. T. H., Theall, K. P., Zhang, L., Hsieh, M.-C., Pollack, L. A., & Wu, X.-C. (2022). Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients. Clinical Colorectal Cancer, 21(2), e62–e75. https://doi.org/10.1016/j.clcc.2021.09.008.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Miftahul Jannah, Syamsu Rijal, Nur Aulia, Sri Julyani, Berry Erida Hasbi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
